Literature DB >> 10202825

CD4+ and CD8+ lymphocytes and HIV RNA in HIV infection: high baseline counts and in particular rapid decrease of CD8+ lymphocytes predict AIDS.

D Kvale1, P Aukrust, K Osnes, F Müller, S S Frøland.   

Abstract

OBJECTIVE: To study the progression of HIV infection in relation to immunological and virological variables with emphasis on the role of CD8+ lymphocytes.
DESIGN: Prospective follow-up from October 1991 of patients observed for at least 18 months allowing nucleoside analogue monotherapy. Peripheral CD4+ and CD8+ lymphocyte counts, HIV RNA, and soluble CD8 were analysed by statistics allowing the evaluation of serial data, avoiding time points with concurrent infections.
SETTING: Tertiary university clinic. PATIENTS: Forty-nine patients were followed for 52.6 months, baseline CD4+ count of 300 x 10(6)/l, sample interval of 5.9 months (medians). MAIN OUTCOME MEASURES: AIDS, death, and CDC groups B- or C-related events.
RESULTS: AIDS developed in 28% of patients. Baseline CD8+ counts above the median were significantly associated with AIDS development; the best Cox model included CD8+ cells and the log10RNA/CD4 ratio. A decline in CD8+ counts relative to baseline most significantly predicted AIDS, along with higher baseline RNA and actual CD4+ counts of less than 200 x 10(6)/l. Levels of soluble CD8 in the blood relative to total CD8+ cells significantly increased in patients developing AIDS. Death occurred in 16% of the patients, and was only predicted by high CD8+ cell counts at baseline. CDC B- and C-related events occurred in 35% of the patients and were best predicted by high baseline CD8+ counts and high RNA levels.
CONCLUSIONS: The serial quantitation of CD8+ lymphocytes gave highly significant predictive information on the natural progression of HIV infection in patients with moderate to severe immune deficiency. Our data suggest that the hyperactivation of CD8+ lymphocytes is an important factor leading to a numerical decrease of CD8+ lymphocytes in progressive HIV infection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10202825     DOI: 10.1097/00002030-199902040-00007

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  4 in total

1.  Combined Env- and Gag-specific T cell responses in relation to programmed death-1 receptor and CD4 T cell loss rates in human immunodeficiency virus-1 infection.

Authors:  F O Pettersen; K Taskén; D Kvale
Journal:  Clin Exp Immunol       Date:  2010-05-10       Impact factor: 4.330

2.  Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial.

Authors:  Jean-Michel Molina; Birgit Grund; Fred Gordin; Ian Williams; Mauro Schechter; Marcello Losso; Matthew Law; Ernest Ekong; Noluthando Mwelase; Athanasios Skoutelis; Martin J Wiselka; Linos Vandekerckhove; Thomas Benfield; David Munroe; Jens D Lundgren; James D Neaton
Journal:  Lancet HIV       Date:  2018-01-16       Impact factor: 16.070

3.  A parameter for IL-10 and TGF-ß mediated regulation of HIV-1 specific T cell activation provides novel information and relates to progression markers.

Authors:  Andreas Lind; Kristin Brekke; Frank Olav Pettersen; Tom Eirik Mollnes; Marius Trøseid; Dag Kvale
Journal:  PLoS One       Date:  2014-01-09       Impact factor: 3.240

4.  CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus-Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC).

Authors:  Adam Trickey; Margaret T May; Philipp Schommers; Jan Tate; Suzanne M Ingle; Jodie L Guest; M John Gill; Robert Zangerle; Mike Saag; Peter Reiss; Antonella d'Arminio Monforte; Margaret Johnson; Viviane D Lima; Tim R Sterling; Matthias Cavassini; Linda Wittkop; Dominique Costagliola; Jonathan A C Sterne
Journal:  Clin Infect Dis       Date:  2017-09-15       Impact factor: 9.079

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.